138 related articles for article (PubMed ID: 1975959)
1. Clinical relevance of immunocytochemical detection of multidrug-resistance-associated P-glycoprotein in hematologic malignancies.
Musto P; Cascavilla N; Di Renzo N; Ladogana S; La Sala A; Melillo L; Nobile M; Matera R; Lombardi G; Carotenuto M
Tumori; 1990 Aug; 76(4):353-9. PubMed ID: 1975959
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance (MDR) genes in haematological malignancies.
Nooter K; Sonneveld P
Cytotechnology; 1993; 12(1-3):213-30. PubMed ID: 7765326
[TBL] [Abstract][Full Text] [Related]
3. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications.
Goasguen JE; Dossot JM; Fardel O; Le Mee F; Le Gall E; Leblay R; LePrise PY; Chaperon J; Fauchet R
Blood; 1993 May; 81(9):2394-8. PubMed ID: 8097634
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of P-glycoprotein expression in haematological malignancies.
Nooter K; Sonneveld P
Leuk Res; 1994 Apr; 18(4):233-43. PubMed ID: 7909572
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia.
Del Poeta G; Stasi R; Aronica G; Venditti A; Cox MC; Bruno A; Buccisano F; Masi M; Tribalto M; Amadori S; Papa G
Blood; 1996 Mar; 87(5):1997-2004. PubMed ID: 8634450
[TBL] [Abstract][Full Text] [Related]
6. The role of P-glycoprotein in drug-resistant hematologic malignancies.
Dalton WS; Grogan TM; Miller TP
Cancer Treat Res; 1991; 57():187-208. PubMed ID: 1686717
[No Abstract] [Full Text] [Related]
7. The expression of the multidrug transporter P-170 glycoprotein in remission phase is associated with early and resistant relapse in multiple myeloma.
Musto P; Lombardi G; Matera R; Carotenuto M
Haematologica; 1991; 76(6):513-6. PubMed ID: 1687943
[TBL] [Abstract][Full Text] [Related]
8. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission.
Musto P; Melillo L; Lombardi G; Matera R; di Giorgio G; Carotenuto M
Br J Haematol; 1991 Jan; 77(1):50-3. PubMed ID: 1671821
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of multidrug resistance in Plasmodium and Leishmania: detection of P-glycoprotein-like components.
Grogl M; Martin RK; Oduola AM; Milhous WK; Kyle DE
Am J Trop Med Hyg; 1991 Jul; 45(1):98-111. PubMed ID: 1678253
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and northern blot analysis.
Wulf G; Kluding H; Ho AD; Doerner M; Doehner H; Manegold C; Hunstein W
Leuk Res; 1994 Jul; 18(7):475-84. PubMed ID: 7912754
[TBL] [Abstract][Full Text] [Related]
11. Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract.
Naito S; Sakamoto N; Kotoh S; Goto K; Matsumoto T; Kumazawa J
Eur Urol; 1992; 22(2):158-62. PubMed ID: 1362155
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein expression in de novo acute myeloid leukemia.
Del Poeta G; Venditti A; Aronica G; Stasi R; Cox MC; Buccisano F; Bruno A; Tamburini A; Suppo G; Simone MD; Epiceno AM; Del Moro B; Masi M; Papa G; Amadori S
Leuk Lymphoma; 1997 Oct; 27(3-4):257-74. PubMed ID: 9402325
[TBL] [Abstract][Full Text] [Related]
14. Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma.
Naito S; Sakamoto N; Kotoh S; Goto K; Matsumoto T; Kumazawa J
Eur Urol; 1993; 24(1):156-60. PubMed ID: 8103456
[TBL] [Abstract][Full Text] [Related]
15. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay.
Ludescher C; Hilbe W; Eisterer W; Preuss E; Huber C; Gotwald M; Hofmann J; Thaler J
J Natl Cancer Inst; 1993 Nov; 85(21):1751-8. PubMed ID: 8105101
[TBL] [Abstract][Full Text] [Related]
16. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
Theyer G; Schirmböck M; Thalhammer T; Sherwood ER; Baumgartner G; Hamilton G
J Urol; 1993 Nov; 150(5 Pt 1):1544-7. PubMed ID: 8105110
[TBL] [Abstract][Full Text] [Related]
17. Detection of the multidrug resistant phenotype in human tumours by monoclonal antibodies and the streptavidin-biotinylated phycoerythrin complex method.
Volm M; Efferth T; Bak M; Ho AD; Mattern J
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):743-9. PubMed ID: 2565814
[TBL] [Abstract][Full Text] [Related]
18. Studies on low-level MDR cells.
Belvedere G; Dolfini E
Cytotechnology; 1993; 12(1-3):257-64. PubMed ID: 7765328
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric analysis of multidrug-resistance-associated antigen (P-glycoprotein) and DNA ploidy in human colon cancer.
Danova M; Giordano M; Erba E; Palmeri S; Candiloro V; Riccardi A; Ucci G; Mazzini G; D'Incalci M; Ascari E
J Cancer Res Clin Oncol; 1992; 118(8):575-80. PubMed ID: 1355483
[TBL] [Abstract][Full Text] [Related]
20. p-glycoprotein expression in malignant melanoma.
Fuchs B; Ostmeier H; Suter L
J Cancer Res Clin Oncol; 1991; 117(2):168-71. PubMed ID: 1672531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
